Viatris wins court decision on AstraZeneca Symbicort patent
jsolie         

A federal court in West Virginia has invalidated a patent applying to AstraZeneca's (NASDAQ:AZN) asthma treatment Symbicort (budesonide/formoterol), a victory for Viatris (NASDAQ:VTRS).
The court found that U.S.Â Patent No. 10,166,247 is invalid due toÂ lack of written description and lack of enablement.
Viatris (VTRS) noted that four Symbicort patents have been found to be either not infringed or invalid.
The US FDA granted approval of Viatris' (VTRS) Symbicort generic, known as Breyna, in March. It has not launched, however, due to the ongoing litigation.